Michael T. Tetzlaff, MD, PhD
UCSF
Pathology, Box 1780
1701 Divisadero Street, Room 268
San Francisco, CA 94115
United States
Dr. Tetzlaff’s primary research interests have been in the field of melanoma in a variety of different settings. He is the current co-leader of the Pathologic Response Assessment Working Group for the International Neoadjuvant Melanoma Consortium and has published the first set of recommendations for pathologic handling and assessment of neoadjuvant treated melanoma specimens. He has provided pathologic support in multiple neoadjuvant clinical trials and has led international efforts to identify pathologic predictors of response and resistance to neoadjuvant therapy in melanoma. He is currently providing central pathology review for a number of industry and cooperative group neoadjuvant clinical trials in melanoma. In addition, Dr. Tetzlaff has led translational studies in melanoma to understand molecular-genetic drivers of melanoma brain metastasis, biomarkers predictive of response/resistance to targeted and immune checkpoint blockade therapy (including immune markers, fecal microbiome markers, and molecular-genetic biomarkers) and molecular-genetic drivers of melanoma disease progression among patients with stage III disease (both clinically occult and clinically evident sub-groups). Dr. Tetzlaff has also led international efforts to identify molecular genetic drivers of ocular-adnexal sebaceous carcinoma and was among the first to show distinct genetic subgroups of this disease. Dr. Tetzlaff’s lab also studied prognostic biomarkers in Merkel cell carcinoma and specifically identified not only the density of the tumor associated T cell infiltrate but also the quality of the T cell repertoire (using T cell receptor sequencing) to identify patients with a distinctive survival advantage. Dr. Tetzlaff has been part of multiple international efforts in Merkel cell carcinoma, including the recent SITC Expert Panel and an NIH expert panel. Dr. Tetzlaff led the immunohistochemistry working group for the NCI-Cancer Immune Monitoring Centers (NCI-CIMAC) and also was the Executive Officer for the Translational Research Program for the Alliance for Clinical Trials cooperative groups. He is currently the Associate Editor for Modern Pathology and The Journal of Cutaneous Pathology and serves on the Editorial Board for American Journal of Surgical Pathology, Laboratory Investigation, and Human Pathology.
Dr. Tetzlaff’s current focus is in education and clinical dermatopathology within the Dermatopathology and Oral Pathology Unit at UCSF.
- Tetzlaff MT, Singh RR, Seviour EG, Curry JL, Hudgens CW, Bell D, Wimmer DA, Ning J, Czerniak BA, Zhang L, Davies MA, Prieto VG, Broaddus RR, Ram P, Luthra R, Esmaeli B. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol 240(1):84-95, 9/2016. e-Pub 6/2016. PMID: 27287813.
- Tetzlaff MT, Curry JL, Ning J, Sagiv O, Kandl TL, Peng B, Bell D, Routbort M, Hudgens CW, Ivan D, Kim TB, Chen K, Eterovic AK, Shaw K, Prieto VG, Yemelyanova A, Esmaeli B. Distinct biological types of ocular adnexal sebaceous carcinoma: HPV-driven and virus- negative tumors arise through non-overlapping molecular-genetic alterations. Clin Cancer Res 25(4):1280-1290, 2/2019. e-Pub 11/2018. PMID: 30420449.
- Tetzlaff MT, Messina J, Stein JE, Xu X, Amaria RN, Blank C, Van De Wiel B, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, Mitchell T, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM and Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology 29(8):1861-1868., 8/2018.
- Amaria RN*, Menzies AM*, Burton EM*, Scolyer RA*, Tetzlaff MT*, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 20(7):e378-e389, 7/2019. PMID: 31267972.
- Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT*, Wargo JA*. *Indicates co-senior authors. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. e- Pub 10/2018. PMID: 30297909.
- Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-193, 2/2018. e-Pub 1/2018. PMID: 29361468.
- Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 44(2):158-176, 2/2017. e-Pub 12/2016. PMID: 27859479.
- Feldmeyer L, Hudgens CW, Lyons GR, Nagarajan P, Aung PP, Curry JL, Torres Cabala CA, Mino B, Rodriguez-Canales J, Reuben A, Chen PL, Ko JS, Billings SD, Bassett RL, Wistuba II, Cooper ZA, Prieto VG, Wargo JA, Tetzlaff MT. Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. Clin Cancer Res. e-Pub 5/2016. PMID: 27166398.
- Farah M, Reuben A, Spassova I, Yang RK, Kubat L, Nagarajan P, Ning J, Li W, Aung PP, Curry JL, Torres-Cabala CA, Hudgens CW, Ugurel S, Schadendorf D, Gumbs C, Little LD, Futreal A, Wistuba II, Prieto VG, Wang L, Wong MK, Wargo JA, Becker JC, Tetzlaff MT. T cell repertoire in combination with T cell density predicts clinical outcomes in patients with Merkel cell carcinoma. J Invest Dermatol. 2020 Nov;140(11):2146-2156.
- Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu LE, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV, Davies MA, Scolyer RA. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol. 2020 Nov;31(11):1569-1579.
- 1993 Deutsche Akademische Auschtauschdienst (DAAD) Fellowship, Max Planck Institute for Biophysical Chemistry, Goettingen Germany, Deutsche Akademische Auschtauschdienst (DAAD)
- 1994 Division of Developmental Biology, Student Fellowship, Max Planck Institute for Biophysical Chemistry Student Fellowship, Max Planck Institute for Biophysical Chemistry, Goettingen Germany
- 1993 Phi Beta Kappa, The University of Texas at Austin
- 1995 Hudson Scholar, Baylor College of Medicine Houston, Texas
- 1995 Presidential Scholar, Baylor College of Medicine Houston, Texas
- 1998 Ilmar Kuisk Outstanding Senior Teaching Assistant Award, Cell Biology and Histology Course, Baylor College of Medicine Houston, Texas
- 1998 John J. Trentin Award for Academic Excellence in Graduate School, Baylor College of Medicine, Baylor College of Medicine Houston, Texas
- 1999 Ilmar Kuisk Outstanding Senior Teaching Assistant Award, Cell Biology and Histology Course, Baylor College of Medicine Houston, Texas
- 2003 Outstanding Platform Presentation, Medical Scientist Training Program Annual Retreat, Baylor College of Medicine Houston, Texas
- 2004 Resident's Choice Award for Outstanding Medical Student, Department of Pathology, Baylor College of Medicine Houston, Texas
- 2005 Richard R. Dickason Outstanding Physician Scientist Award, Medical Scientist Training Program (MSTP), Baylor College of Medicine Houston, Texas
- 2007 Leonard R. Jarrett Research Symposium Resident Platform Presentation, Hospital for the University of Pennsylvania, Department of Pathology and Laboratory Medicine
- 2007 Ronni A. Ladoto Residence Excellence in Teaching Award, Hospital for the University of Pennsylvania, Department of Pathology and Laboratory Medicine
- 2011 Stelwagon Award, Honorable Mention, Dermatology, The College of Physicians of Philadelphia
- 2019 Shirley Stein Scientific Endowed Research Award, The University of Texas MD Anderson Cancer Center, Houston, Texas